Bright Minds Biosciences (NASDAQ:DRUG) Upgraded to “Strong-Buy” at Cantor Fitzgerald
Cantor Fitzgerald upgraded shares of Bright Minds Biosciences (NASDAQ:DRUG – Free Report) to a strong-buy rating in a report issued on Tuesday morning,Zacks.com reports. Cantor Fitzgerald also issued estimates for Bright Minds Biosciences’ FY2025 earnings at ($0.87) EPS. Several other equities research analysts have also recently weighed in on the stock. Chardan Capital began coverage […]
Cantor Fitzgerald upgraded shares of Bright Minds Biosciences (NASDAQ:DRUG – Free Report) to a strong-buy rating in a report issued on Tuesday morning,Zacks.com reports. Cantor Fitzgerald also issued estimates for Bright Minds Biosciences’ FY2025 earnings at ($0.87) EPS. Several other equities research analysts have also recently weighed in on the stock. Chardan Capital began coverage […]
